Excerpt from: National Multiple Sclerosis Society (click for full article)
Despite significant progress in the development of treatments for people with relapsing forms of multiple sclerosis, there are few treatment options for people with progressive forms of MS. The newly formed International Collaborative on Progressive MS has published an opinion paper outlining challenges in developing therapies for progressive MS and identifying key research priorities to propel efforts to stop MS progression. The Collaborative is the greatest effort to date aiming at speeding research on progressive MS, and is formed of the MS Societies of Canada, Italy, Netherlands, the UK and the US, and the MS International Federation. The paper, by lead author Robert J. Fox, MD (Mellen Center for Multiple Sclerosis, Neurological Institute, and Lerner College of Medicine, Cleveland Clinic) and colleagues, identifies five key priority areas for research, and was published in the Multiple Sclerosis Journal (Online First, August 23, 2012).
“Overcoming the challenges of progressive MS is a key objective of the Society’s Strategic Response to MS,” says Timothy Coetzee, PhD, Chief Research Officer of the National MS Society and member of the Collaborative. “This is just one of the ways we’re collaborating worldwide to speed clinical trials in progressive MS.”